SAMRATPH.BO · BSE

SAMRAT PHARMACHEM LTD.

₹232

+4.01% (+₹8.95)

Prev. close

₹223.05

Volume

2,262

As of

25 Sept 2026

Price history

₹232+₹19.25 (+9.05%) · 3M
24 Jun 2026 → 25 Sept 2026
₹286.6₹212.7524 Jun17 Jul11 Aug02 Sept25 Sept
Daily closes · updates after each session

No analyst calls on this stock in the last 90 days yet.

Explore by date range →

Analyst opinions

No analyst calls on SAMRAT PHARMACHEM LTD. in the last 90 days.

Fundamentals

About SAMRAT PHARMACHEM LTD.

Samrat Pharmachem Limited manufactures and sells pharmaceutical chemicals in India. It offers 3-5-di iodosalicylic acid, ammonium iodide, cadmium iodide, calcium iodate, clioquinol, copper iodide, ethyl iodide, ethylenediamine dihydroiodide, hydroiodic acid, iodine, iodine monochloride, iodoquinol, methyl iodide, n-iodo succinimide, periodic acid, potassium iodate and iodide, potassium metaper iodate, povidone iodine, sodium iodate and iodide, and sodium metaper iodate. The company serves the agrochemical, animal feed, chemical, cosmetics, food, pharmaceutical, printing, and textile industries. It also exports its products to the United States, Europe, Africa, Asia, the Middle East, and internationally. Samrat Pharmachem Limited was incorporated in 1992 and is based in Mumbai, India.

Details

Sector

Basic Materials

Industry

Chemicals

CEO

Mr. Lalit Damodar Mehta

Headquarters

Mumbai

Employees

30

Key stats

Market cap

₹68.92 Cr

Dividend yield

0.44%

EPS (TTM)

₹-7.13

Beta (1Y · daily vs NIFTY 50)

0.82

Beta (5Y · monthly vs NIFTY 50)

0.66

Shares float

11.89 L

EPS · quarter ended Jun 2026

₹2.84

Financial Performance

01 · Financials

-200 Cr0 Cr200 Cr400 Cr₹-25%0%25%50%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDARevenue growth YoY

Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.

02 · Earnings Per Share (EPS)

-50050100₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

00111₹0%0.3%0.5%0.8%22 Sept 2218 Sept 2319 Sept 2418 Sept 25
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-50%0%50%100%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr50 Cr100 Cr150 Cr₹0×1×2×3×FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr50 Cr100 Cr150 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

-20 Cr-10 Cr0 Cr10 Cr20 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹179.02 Cr₹221.81 Cr₹310.65 Cr₹281.58 Cr₹285.86 Cr₹289.72 Cr
EBITDA₹9.13 Cr₹24.89 Cr₹24.10 Cr₹3.72 Cr₹11.03 Cr₹-1.83 Cr
₹5.33 Cr₹17.19 Cr₹16.63 Cr₹2.16 Cr₹7.11 Cr₹-3.31 Cr
Diluted EPS₹17.26₹55.62₹53.83₹7₹23.02₹-10.72

Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
——₹116.59 Cr₹121.74 Cr₹121.49 Cr₹124.42 Cr
——₹18.66 Cr₹8.45 Cr₹9.91 Cr₹10.71 Cr
Stockholders' equity——₹63.14 Cr₹65.00 Cr₹71.80 Cr₹68.18 Cr

Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
——₹-9.44 Cr₹9.41 Cr₹-10.09 Cr₹8.88 Cr
Investing cash flow——₹-3.00 Cr₹-40.60 L₹-48,000₹-2.57 Cr
——₹9.60 Cr₹-11.20 Cr₹47.71 L₹-47.19 L
Capital expenditure——₹-1.46 Cr₹-66.67 L₹-50.71 L₹-3.10 Cr
End cash position——₹11.86 Cr₹9.67 Cr₹4.83 L₹5.88 Cr

Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

12 · Peer Comparison

Basic Materials

Company
UltraTech Cement Limited₹3.25 L Cr₹11,15538.14.2410.7%0.31+16.6%-8.1%
JSW Steel Limited₹3.14 L Cr₹1,27712.73.1322.3%1.19+9.3%+11.2%
Hindustan Zinc Limited₹2.48 L Cr₹588.9514.510.9661.1%0.39+18.6%+26.2%
Tata Steel Limited₹2.38 L Cr₹188.0220.92.3310.6%0.90+6.2%+8.9%
Asian Paints Limited₹2.29 L Cr₹2,44449.510.7320.2%0.18+5.1%+1.7%
Hindalco Industries Limited₹2.18 L Cr₹97713.61.609.8%0.73+15.0%+31.0%
Grasim Industries Limited₹2.15 L Cr₹3,19137.82.084.8%2.20+18.2%+14.8%
Solar Industries India Limited₹1.79 L Cr₹19,48087.028.4426.7%0.29+30.6%+38.9%
Vedanta Aluminium Metal Limited₹1.69 L Cr₹429.442.7—————
Pidilite Industries Limited₹1.55 L Cr₹1,517.258.814.3122.6%0.04+11.1%+1.4%
JINDAL STEEL LIMITED₹1.18 L Cr₹1,164.844.12.316.6%0.44+5.5%+10.8%
SAMRAT PHARMACHEM LTD.₹68.92 Cr₹223.05—1.01-4.9%0.16+1.4%-29.5%

Ranked by market cap within Basic Materials, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Annual reports

Show all 30

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

SAMRATPH.BO

Samrat Pharmachem: Q1 FY27 Results Released

InvestyWise · 1 month ago